# Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

> **NCT03553537** · PHASE3 · UNKNOWN · sponsor: **Southwest Hospital, China** · enrollment: 100 (estimated)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03553537
- **Lead sponsor:** Southwest Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06
- **Primary completion:** 2021-07
- **Final completion:** 2021-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2018-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03553537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03553537, "Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03553537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*